Sharps Technology Files Proxy Materials
Ticker: STSSW · Form: DEFA14A · Filed: Jul 9, 2024 · CIK: 1737995
| Field | Detail |
|---|---|
| Company | Sharps Technology Inc. (STSSW) |
| Form Type | DEFA14A |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
TL;DR
Sharps Tech filed proxy docs, looks like they're getting ready for a shareholder vote.
AI Summary
Sharps Technology Inc. filed a Definitive Additional Materials filing (DEFA14A) on July 9, 2024. This filing concerns proxy materials for the company, which is incorporated in Nevada and operates in the Surgical & Medical Instruments & Apparatus industry. The company's principal executive offices are located in Melville, NY.
Why It Matters
This filing indicates that Sharps Technology Inc. is proceeding with shareholder communications and potential corporate actions requiring shareholder approval, as outlined in their proxy statement.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Sharps Technology Inc. (company) — Registrant
- 20240709 (date) — Filing Date
- Melville, NY (location) — Business Address
FAQ
What type of filing is this DEFA14A for Sharps Technology Inc.?
This filing is for Definitive Additional Materials, as indicated by the checkmark next to 'Definitive Additional Materials' and the filing type DEFA14A.
When was this filing submitted to the SEC?
The filing was submitted on July 9, 2024, as indicated by the accession number and header information.
What is the primary business of Sharps Technology Inc.?
Sharps Technology Inc. operates in the 'Surgical & Medical Instruments & Apparatus' industry, with the SIC code 3841.
Where are Sharps Technology Inc.'s principal executive offices located?
The company's business and mail address is located at 105 Maxess Road, Ste. 124, Melville, NY 11747.
Is there a fee associated with this filing?
No fee was required for this filing, as indicated by the checkmark next to 'No fee required.'
Filing Stats: 1,417 words · 6 min read · ~5 pages · Grade level 12.6 · Accepted 2024-07-09 09:13:56
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value STSS NASDAQ Capital Mark
Filing Documents
- formdefa14a.htm (DEFA14A) — 55KB
- 0001493152-24-026584.txt ( ) — 56KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 9, 2024 SHARPS TECHNOLOGY, INC. /s/ Robert Hayes Robert Hayes Chief Executive Officer Exhibit 99.1 Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company’s continued growth. Voting deadline is Friday, July 12, at 11:59 p.m. Eastern Time. NEW YORK, JULY 9, 2024 – Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company’s Chief Executive Officer. Dear Fellow Shareholders: In order to continue Sharps Technology’s solid progress toward achieving its goals, I want to share with you the importance of the three proposals on the shareholder ballot and ask you to take a few moments to vote to approve them. Up for vote on the ballot are the following three proposals: To increase the authorized number of shares of common stock, if required for future equity transactions. To effectuate a reverse stock split of the Company’s common stock, at our discretion, at a ratio of up to 1-for-8, if required to maintain our Nasdaq listing. To issue securities in non-public offerings where the maximum discount will not exceed 20% below the market price of the Company’s common stock. Our leadership team is moving forward aggressively to increase the Company’s valuation through strategic partnerships and customer opportunities that will drive the need to expand our manufacturing capacity in Europe and the United States. We believe that p